US group seeks to block Gilead drug patent in India

November 24, 2013 by Penelope Macrae

A US-based patient rights group said Saturday it has sought to block a bid by California-based Gilead Sciences to obtain an Indian patent for a potentially blockbuster drug to treat hepatitis C.

New York's Initiative for Medicines, Access & Knowledge (I-MAK), which works to ensure affordable access to drugs, said it opposed the for the sofosbuvir to treat the liver-destroying disease on the grounds that it is "old science".

Patent law in India, known as the "pharmacy to the world" for its vast generic drug industry that turns out cheaper copycat versions of life-saving branded medicines, is tougher than in many other countries.

The strict regime has led to a string of expensive intellectual property setbacks for Western drugmakers such as Roche and Pfizer in the quickly growing Indian pharmaceutical market.

"India's doesn't give monopolies for old science or for compounds already in the public domain," Tahir Amin, director of I-MAK said.

"We believe this patent on sofosbuvir does not deserve to be granted in India and have the legal grounds to prove it," he said in a statement.

I-MAK filed a "patent opposition" suit Thursday at India's Patent Office leaving Gilead, a giant biotechnology company, facing a potentially long battle to secure the rights to market the drug, said international medical charity Medecins Sans Frontieres (MSF), which is backing I-MAK.

A decision by Indian regulators on whether to grant the patent will hinge on whether they deem Gilead's drug to be a major new scientific development.

The patent opposition move is an attempt to ensure generic versions of the drug can be developed that will be affordable for people in developing countries infected with chronic hepatitis C, which causes deadly diseases such as liver cancer and cirrhosis, Amin said.

Gilead is expected to charge around $80,000 for a single course of treatment with sofosbuvir when it becomes available in the United States, said MSF.

Even if offered at a fraction of this price in developing countries, "this drug will be way beyond the reach of patients", MSF Access Campaign spokeswoman Shailly Gupta told AFP.

Gilead, one of the world's biggest makers of HIV drugs, did not immediately respond to an emailed AFP request for comment.

Drug analysts see sofosbuvir, which is to be marketed under the trade name Sovaldi, as the prize gain from Gilead's $11-billion purchase of biotechnology company Pharmasset in late 2011.

The drug is still being reviewed by regulators but could be released in US and European markets next year.

The World Health Organization estimates there are 184 million people infected with hepatitis C worldwide through sources such as transfusions, with the disease causing half a million deaths annually.

Current treatments can take up to a year and only cure about 75 percent of patients.

Gilead's daily pill can cure up to 90 percent of patients infected with the most common form of the virus within three months and eliminates the need for the injectable drug interferon, which can cause unpleasant side-effects.

Sofosbuvir is the first of several oral hepatitis C drugs expected to come to market soon but they are compounds that are "relatively simple and cheap to make", Andrew Hill, a pharmacologist at Britain's Liverpool University, was quoted as saying in the statement.

Hill has published a study suggesting that sofosbuvir could be produced for as little as $62 to $134 for a 12-week treatment course.

Explore further: US panel backs Gilead Sciences' hepatitis C drug (Update)

Related Stories

US panel backs Gilead Sciences' hepatitis C drug (Update)

October 23, 2013
U.S. Food and Drug Administration advisers on Friday unanimously voted in favor of a highly anticipated hepatitis C drug from Gilead Sciences that holds promise for millions infected with the liver-destroying virus.

Roche drops India patent for breast-cancer drug (Update)

August 17, 2013
Swiss pharmaceutical giant Roche says it is abandoning a patent for top-selling breast cancer drug Herceptin in the Indian market, paving the way for local drugmakers to make a cheaper generic version.

FDA reviews two promising new drugs for hepatitis C

October 22, 2013
Doctors may soon have two new drug options to treat patients with hepatitis C, just as the liver-destroying virus becomes a major public health issue for millions of Americans reaching retirement age.

Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant

October 31, 2013
New drug therapies offer promise to some hepatitis C sufferers whose transplanted livers are threated by a recurrence of the disease, including some patients who have had no treatment options.

India revokes cancer drug patent in fresh industry blow

August 2, 2013
India has revoked a local patent granted to Britain's GlaxoSmithKline for a breast cancer drug in the latest blow to global companies seeking a bigger presence in the country's $13 billion medicine market.

Recommended for you

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

Opioids overused in migraine treatment, regardless of race, study finds

August 17, 2017
African-Americans are more likely to experience debilitating migraine headaches than whites, but a new study probing the issue found no evidence of racial disparities in treatment practices.

Finding better ways to reduce serious drug side effects

August 14, 2017
Many of the medicines we depend on to treat disease—and even to save our lives—pose potentially serious risks along with their benefits. Data from the U.S. Centers for Disease Control and Prevention indicate that about ...

Ultrasound-triggered liposomes for on-demand, local anesthesia

August 10, 2017
Researchers at Boston Children's Hospital have found a new way to non-invasively relieve pain at local sites in the body; such systems could one day improve pain management by replacing addictive opioids and short-lasting ...

Independent pharmacies and online coupons help patients save money on drugs

August 8, 2017
Uninsured patients or those with limited prescription drug coverage can save significant money by buying their drugs at independent pharmacies instead of big box, grocery or chain drug stores and by using discount coupons, ...

New study generates more accurate estimates of state opioid and heroin fatalities

August 7, 2017
Although opioid and heroin deaths have been rising dramatically in the U.S., the magnitude of the epidemic varies from state to state, as does the relative proportion of opioid vs heroin poisonings. Further complicating the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.